Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care
Search for other papers by Christina Barrington in
Current site
Google Scholar
PubMed
Search for other papers by Rondeep Brar in
Current site
Google Scholar
PubMed
Search for other papers by Laura Bray in
Current site
Google Scholar
PubMed
Search for other papers by Stephen Colvill in
Current site
Google Scholar
PubMed
Search for other papers by Erin R. Fox in
Current site
Google Scholar
PubMed
Search for other papers by Lalan S. Wilfong in
Current site
Google Scholar
PubMed
Search for other papers by Clifford Goodman in
Current site
Google Scholar
PubMed
A recent NCCN discussion panel on oncology drug shortages in the United States illuminated the stark contrast between the nation’s health care expenditure and the challenge of ensuring drug availability for cancer treatment. Industry experts across health care disciplines discussed the root causes and consequences of drug shortages, shedding light on the significant impact these shortages have on patient care and health care operations. They also discussed broader systemic failures, such as the lack of manufacturing transparency and flawed supply chains. The conversation called for immediate action, including advocacy and improved drug distribution management, an emphasis on resilience, legislative measures to bolster supply chain robustness, and a complete systematic overhaul to guarantee consistent drug access for cancer care.
Disclosures: R. Brar has disclosed receiving honoraria from Apellis, Alexon Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation. S. Colvill has disclosed serving as a consultant for Medicines360; and owning equity interest/stock options for Pfizer Inc. L.S. Wilfong has disclosed serving as a consultant for AbbVie, Inc., AstraZeneca Pharmaceuticals LP, and Genzyme Corporation. C. Goodman has disclosed serving as a consultant for Bayer HealthCare, Janssen Scientific Affairs, LLC, Medtronic, Inc., Merck & Co., Inc., and Sandoz. The remaining presenters disclosed no relevant financial relationships.
© 2019-2024 National Comprehensive Cancer Network